Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation.

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation (2014) 3.28

Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J (2008) 2.29

Atrial fibrillation in congestive heart failure. Heart Fail Clin (2010) 1.07

Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry. J Am Coll Cardiol (2010) 0.92

2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. J Arrhythm (2016) 0.88

Feasibility and efficacy of electrical cardioversion after cardiac resynchronization implantation in patients with permanent atrial fibrillation. J Interv Card Electrophysiol (2012) 0.88

Desperately seeking a randomized clinical trial of resynchronization therapy for patients with heart failure and atrial fibrillation. J Am Coll Cardiol (2006) 0.83

EAARN score, a predictive score for mortality in patients receiving cardiac resynchronization therapy based on pre-implantation risk factors. Eur J Heart Fail (2014) 0.82

Clinical implication of mechanical dyssynchrony in heart failure. J Cardiovasc Ultrasound (2012) 0.81

Cardiac resynchronization therapy: history, present status, and future directions. Ochsner J (2014) 0.81

Impact of chronic atrial fibrillation in patients with severe heart failure and indication for CRT: data of two registries with 711 patients (1999-2006 and 2007-6/2008). Herzschrittmacherther Elektrophysiol (2011) 0.78

Cardiac resynchronization therapy in heart failure patients with atrial fibrillation. Europace (2009) 0.78

Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis. Curr Cardiol Rep (2013) 0.78

Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry. Eur Heart J (2009) 0.78

Resynchronization therapy in the context of atrial fibrillation: benefits and limitations. J Interv Card Electrophysiol (2007) 0.77

Therapeutic and diagnostic role of electrical devices in acute heart failure. Heart Fail Rev (2007) 0.77

Cardiac resynchronization therapy. Ochsner J (2009) 0.77

Atrial fibrillation in patients with heart failure: Role of catheter ablation therapies. Exp Clin Cardiol (2012) 0.76

Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. Circ Heart Fail (2016) 0.75

Use of Cardiac Resynchronisation Therapy - Change of Clinical Settings. Arrhythm Electrophysiol Rev (2014) 0.75

Atrioventricular Junction Ablation In Atrial Fibrillation: Choosing The Right Patient And Pacing Device. J Atr Fibrillation (2015) 0.75

A review on atrioventricular junction ablation and pacing for heart rate control of atrial fibrillation. J Geriatr Cardiol (2015) 0.75

Comparison of the rhythm control treatment strategy versus the rate control strategy in patients with permanent or long-standing persistent atrial fibrillation and heart failure treated with cardiac resynchronization therapy - a pilot study of Cardiac Resynchronization in Atrial Fibrillation Trial (Pilot-CRAfT): study protocol for a randomized controlled trial. Trials (2014) 0.75

Cardiac Resynchronization in Patients with Atrial Fibrillation. J Atr Fibrillation (2015) 0.75

Co-Morbidities and Cardiac Resynchronization Therapy: When Should They Modify Patient Selection? J Atr Fibrillation (2015) 0.75

An Overview of Current Cardiac Resynchronization Therapy. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2013) 0.75

Relevance of Monitoring Atrial Fibrillation in Clinical Practice. Arrhythm Electrophysiol Rev (2012) 0.75

Fusion beat in patients with heart failure treated with left ventricular pacing: may ECG morphology relate to mechanical synchrony? A pilot study. Cardiovasc Ultrasound (2008) 0.75

Device Management in Heart Failure. Curr Cardiol Rep (2017) 0.75

How to improve outcomes: should we put more emphasis on programming and medical care and less on patient selection? Heart Fail Rev (2012) 0.75

[Indication for CRT]. Herzschrittmacherther Elektrophysiol (2009) 0.75

Atrioventricular junction ablation and pacemaker implantation for heart failure associated with atrial fibrillation: potential issues and therapies in the setting of acute heart failure syndrome. Heart Fail Rev (2011) 0.75

[Pacemaker ECG quiz no. 22. A CRT non-responder with atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2010) 0.75

Strategies for pacemaker programming in acute heart failure. Heart Fail Rev (2011) 0.75

[CRT in atrial fibrillation--methodical and apparatus options in decision-making]. Herzschrittmacherther Elektrophysiol (2008) 0.75

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J (2012) 16.00

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J (2013) 6.17

Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur Heart J (2007) 4.15

2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace (2013) 4.07

A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med (2014) 3.92

A meta-analysis of remote monitoring of heart failure patients. J Am Coll Cardiol (2009) 3.61

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35

Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA (2013) 2.88

Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. Eur Heart J (2004) 2.87

Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63

The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant (2010) 2.59

Guidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Europace (2007) 2.58

Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood (2004) 2.52

Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2004) 2.43

2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J (2010) 2.36

Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J (2008) 2.29

Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood (2011) 2.29

Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study. Br J Haematol (2013) 2.28

Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med (2007) 2.27

Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation (2004) 2.11

Indications for the use of diagnostic implantable and external ECG loop recorders. Europace (2009) 2.06

The European cardiac resynchronization therapy survey. Eur Heart J (2009) 2.04

Atrial fibrillation after isolated coronary surgery affects late survival. Circulation (2008) 2.02

Significance of total and differential leucocyte count in patients with acute myocardial infarction treated with primary coronary angioplasty. Eur Heart J (2006) 1.99

Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol (2008) 1.97

Clinical evaluation of defibrillation testing in an unselected population of 2,120 consecutive patients undergoing first implantable cardioverter-defibrillator implant. J Am Coll Cardiol (2012) 1.95

MitraClip® therapy in patients with end-stage systolic heart failure. Eur J Heart Fail (2011) 1.95

Delayed defibrillation testing in patients implanted with biventricular ICD (CRT-D): a reliable and safe approach. J Cardiovasc Electrophysiol (2005) 1.95

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation (2003) 1.93

Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol (2010) 1.92

Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J (2007) 1.90

A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft VentriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study. Eur Heart J (2009) 1.89

High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis (2006) 1.88

Clinical implications of reconnection between the left atrium and isolated pulmonary veins provoked by adenosine triphosphate after extensive encircling pulmonary vein isolation. J Cardiovasc Electrophysiol (2007) 1.88

Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study. J Am Coll Cardiol (2007) 1.85

Are we not over-estimating the prevalence of coeliac disease in the general population? Ann Med (2010) 1.84

HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Heart Rhythm (2008) 1.79

Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol (2008) 1.79

Echocardiographic quantification of left ventricular asynchrony predicts an acute hemodynamic benefit of cardiac resynchronization therapy. J Am Coll Cardiol (2002) 1.77

Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol (2002) 1.76

Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. Int J Cardiol (2008) 1.71

HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations: developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Failure Society of America (HFSA). Endorsed by the Heart Rhythm Society, the European Heart Rhythm Association (a registered branch of the ESC), the American College of Cardiology, the American Heart Association. Europace (2008) 1.70

Magnetic resonance imaging in individuals with cardiovascular implantable electronic devices. Europace (2008) 1.68

Failure of implantable cardioverter-defibrillator leads: a matter of lead size? Heart Rhythm (2012) 1.68

A case of Guillain-Barrè syndrome following Staphylococcus aureus endocarditis. Int J Cardiol (2006) 1.67

Nutritional parameters associated with prolonged hospital stay among ambulatory adult patients. CMAJ (2010) 1.65

Feasibility, safety, and short-term outcome of leadless ultrasound-based endocardial left ventricular resynchronization in heart failure patients: results of the wireless stimulation endocardially for CRT (WiSE-CRT) study. Europace (2014) 1.65

Impact of cardiac resynchronization therapy on the severity of mitral regurgitation. Europace (2011) 1.64

Evaluation of friction of stainless steel and esthetic self-ligating brackets in various bracket-archwire combinations. Am J Orthod Dentofacial Orthop (2003) 1.63

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Rev Esp Cardiol (Engl Ed) (2014) 1.61

Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study. J Hypertens (2006) 1.61

Evaluation of friction of conventional and metal-insert ceramic brackets in various bracket-archwire combinations. Am J Orthod Dentofacial Orthop (2003) 1.60

Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J (2006) 1.58

Comparison of 1-year effects of left ventricular and biventricular pacing in patients with heart failure who have ventricular arrhythmias and left bundle-branch block: the Bi vs Left Ventricular Pacing: an International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias (BELIEVE) multicenter prospective randomized pilot study. Am Heart J (2006) 1.56

Observational study on the beneficial effect of preoperative statins in reducing atrial fibrillation after coronary surgery. Ann Thorac Surg (2007) 1.55

Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. J Am Coll Cardiol (2005) 1.55

2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm (2012) 1.54

Biventricular pacing via a persistent left superior vena cava: report of four cases. Pacing Clin Electrophysiol (2003) 1.54

Variability of coronary venous anatomy in patients undergoing cardiac resynchronization therapy: a high-speed rotational venography study. Heart Rhythm (2007) 1.50

In-vitro fluoride release rates from 9 orthodontic bonding adhesives. Am J Orthod Dentofacial Orthop (2007) 1.50

Proportion of patients needing an implantable cardioverter defibrillator on the basis of current guidelines: impact on healthcare resources in Italy and the USA. Data from the ALPHA study registry. Europace (2010) 1.48

Accuracy and usefulness of fusion imaging between three-dimensional coronary sinus and coronary veins computed tomographic images with projection images obtained using fluoroscopy. Europace (2009) 1.48

Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace (2007) 1.46

2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace (2012) 1.46

Differential change in left ventricular mass and regional wall thickness after cardiac resynchronization therapy for heart failure. Eur Heart J (2006) 1.46

Clinical study regarding the anatomical structures of the right atrial isthmus using intra-cardiac echocardiography: implication for catheter ablation of common atrial flutter. J Interv Card Electrophysiol (2005) 1.45

2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace (2010) 1.45

Prognostic relevance of a non-invasive evaluation of right ventricular function and pulmonary artery pressure in patients with chronic heart failure. Eur J Heart Fail (2013) 1.44

Fluoroscopic left ventricular lead position and the long-term clinical outcome of cardiac resynchronization therapy. Pacing Clin Electrophysiol (2011) 1.44

Identification of a lower grade muconodular subtype of gastric mucinous cancer. Virchows Arch (2004) 1.43

Sustained improvement in left ventricular function after bone marrow derived cell therapy in patients with acute ST elevation myocardial infarction. A 5-year follow-up from the Stem Cell Transplantation in Ischaemic Myocardium Study. Swiss Med Wkly (2012) 1.43

2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail (2010) 1.43

Impact of lesion sets on mid-term results of surgical ablation procedure for atrial fibrillation. J Am Coll Cardiol (2011) 1.43

Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. Leuk Res (2008) 1.42

Feasibility and acute efficacy of radiofrequency ablation of cavotricuspid isthmus-dependent atrial flutter guided by real-time 3D TEE. JACC Cardiovasc Imaging (2011) 1.42

Utility of distinctive local electrogram pattern and aortographic anatomical position in catheter manipulation at coronary cusps. J Cardiovasc Electrophysiol (2010) 1.41

Cardiac resynchronization therapy for heart failure shows great promise. Isr Med Assoc J (2003) 1.41

[Clinical competence certification for advanced heart failure: an emerging need also in Italy?]. G Ital Cardiol (Rome) (2015) 1.40

Electrophysiological and hemodynamic effects of vernakalant and flecainide during cardiac resynchronization in dyssynchronous canine hearts. J Cardiovasc Pharmacol (2014) 1.39

Images in cardiovascular medicine. Hiccups and dysphonic metallic voice: a unique presentation of Twiddler syndrome. Circulation (2006) 1.39

Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal. Circ J (2013) 1.38

Anatomy of pulmonary veins by real-time 3D TEE: implications for catheter-based pulmonary vein ablation. JACC Cardiovasc Imaging (2012) 1.38

What are the costs of heart failure? Europace (2011) 1.36

Overcoming the challenges of single-incision cholecystectomy with robotic single-site technology. Arch Surg (2012) 1.35

Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat (2008) 1.34

Clinical, anatomopathological and genetic pattern of 10 patients with cervical aortic arch. Int J Cardiol (2006) 1.29